FDA 483 OBSERVATION · #198 OF 1,945 MOST-CITED

GMP Training Frequency

FDA cited this observation 154 times across 150 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs154
BY FISCAL YEAR
FY20269
FY202514
FY202411
FY20237
FY20226
FY20219
FY20206
FY201920
FY201816
FY201727
FY201629

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.4× the rate of the average FDA-cited firm (26.7% vs 7.8%), across 150 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

GMP training is not conducted on a continuing basis and with sufficient frequency to assure that employees remain familiar with CGMP requirements applicable to them.

Gehring-Montgomery, Inc. · Warminster, Pennsylvania · Drugs · 2026-08-26

GMP training is not conducted on a continuing basis to assure that employees remain familiar with CGMP requirements applicable to them.

Biokosmes Srl · Bosisio Parini · Drugs · 2026-06-26

GMP training is not conducted on a continuing basis to assure that employees remain familiar with CGMP requirements applicable to them.

Trifluent Pharma LLC · San Antonio, Texas · Drugs · 2026-06-11

GMP training is not conducted to assure that employees remain familiar with CGMP requirements applicable to them.

Nexus Pharmaceuticals, LLC · Lincolnshire, Illinois · Drugs · 2026-06-04

GMP training is not conducted with sufficient frequency to assure that employees remain familiar with CGMP requirements applicable to them.

API Solutions Inc. · Daphne, Alabama · Drugs · 2026-05-27

GMP training is not conducted to assure that employees remain familiar with CGMP requirements applicable to them.

Micro Measurement Laboratories, Inc. · Wheeling, Illinois · Drugs · 2026-04-28

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →